Form 4: IMAX CEO Richard Gelfond Trades Shares Under 10b5-1 Plan
Statement of Changes in Beneficial Ownership
IMAX CEO Richard Gelfond executed transactions involving the purchase and sale of company shares under a pre-arranged 10b5-1 trading plan.
Summary
- Richard L. Gelfond, CEO of IMAX Corp, reported transactions on April 2nd and April 6th, 2026, under a Rule 10b5-1(c) trading plan established on December 9, 2025.
- On April 2nd, 2026, Gelfond exercised stock options to acquire 12,037 common shares at $31.40 per share and subsequently sold these shares for $40.0034 each.
- On April 6th, 2026, Gelfond exercised additional stock options for 12,987 common shares at $31.40 per share and sold them at $40.2621 per share.
- Following these transactions, Gelfond's beneficial ownership includes 765,002 common shares directly held.
- His remaining outstanding equity includes 1,672,451 stock options, 231,562 restricted share units, and 765,002 common shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it reports routine transactions under a pre-established compliance plan rather than indicating new strategic developments or significant changes in management's outlook.
Positives
- The transactions were conducted under a pre-established 10b5-1 plan, which is designed to provide an affirmative defense against insider trading allegations by ensuring trades are planned in advance.
- The CEO is exercising options and selling shares at a price higher than the exercise price, indicating a profitable transaction for the individual.
- The CEO retains a significant number of common shares (765,002) and other equity awards, suggesting continued alignment with shareholder interests.
Negatives
- The CEO is selling a portion of his vested stock options, which could be interpreted by some investors as a signal of reduced confidence, although the 10b5-1 plan mitigates this concern.
- The filing details the sale of shares acquired through option exercises, representing a reduction in direct holdings of those specific shares.
Risks
- While the 10b5-1 plan is in place, any significant future sales by management could still be scrutinized by the market.
- The expiration of stock options on June 7, 2026, is a factor in the timing of these transactions.
Future Outlook
The filing does not contain forward-looking statements or guidance. It solely reports on past transactions executed under a pre-defined plan.
Industry Context
StockSavvy.ai notes that the use of 10b5-1 plans by executives is a common practice in the entertainment technology and media sectors to manage personal stock transactions in a compliant manner, especially for companies with regular reporting cycles.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| 10b5-1 Plan Execution | Transactions were made pursuant to a contract, instruction, or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). | 2025-12-09 | Enhances compliance and reduces risk of insider trading allegations for the reported transactions. |
Stakeholder Impact
- Shareholders: The transactions are conducted under a 10b5-1 plan, which is a standard compliance mechanism. The CEO's continued significant holdings suggest ongoing commitment.
- Employees: No direct impact mentioned.
- Creditors: No direct impact mentioned.
- Suppliers/Customers: No direct impact mentioned.
Next Steps
- The stock options reported in this filing are set to expire on June 7, 2026.
Key Dates
| Date | Description |
|---|---|
| 2016-06-07 | First installment of stock options became exercisable. |
| 2016-09-01 | Second installment of stock options became exercisable. |
| 2016-12-31 | Third installment of stock options became exercisable. |
| 2025-12-09 | Date of the 10b5-1 trading plan. |
| 2026-04-02 | Transaction date for exercise of stock options and sale of common shares. |
| 2026-04-06 | Transaction date for exercise of stock options and sale of common shares. |
| 2026-06-07 | Expiration date for the reported stock options. |
Keywords
IMAX Corp, IMAX, Richard L. Gelfond, Form 4, SEC Filing, Stock Options, 10b5-1 Plan, Insider Trading, Beneficial Ownership, Common Shares, Securities Exchange Act
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.